Operation Dream Job is evolving once again, and now comes through malicious dependencies on bare-bones projects.

A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...

Machine learning is an essential component of artificial intelligence. Whether it’s powering recommendation engines, fraud detection systems, self-driving cars, generative AI, or any of the countless ...

Oh, sure, I can “code.” That is, I can flail my way through a block of (relatively simple) pseudocode and follow the flow. I ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Developer tooling provider Anaconda Inc. today announced that it has closed a Series C funding round worth more than $150 million. Insight Partners led the investment with participation from Mubadala ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...